Labarai

NEW YORK, Yuni 23, 2022 (GLOBE NEWSWIRE) - Reportlinker.com ya ba da sanarwar fitar da rahoton "Global Intravenous Therapy and Intravenous Access Market Girman, Raba da Rahoton Bincike na Masana'antu, Hankali da Hasashen Mai Amfani, Aikace-aikace, Nau'in, Yanki , 2022-2028″ - https://www.reportlinker.com/p06283441/?utm_source=GNW Hanya mafi sauri don shigar da ruwa zuwa sassa daban-daban na jiki shine ta hanyar IV therapy. wannan magani.A wannan yanayin, ya kamata a yi wa mara lafiya magani da wuri-wuri, don haka ana ba da maganin a cikin jijiyar. Jiyya na chemotherapy, maganin rigakafi, antifungals, masu rage ciwo, maganin rigakafi na globulin, da magungunan hawan jini. (IV) wata hanya ce ta isar da magunguna da ruwaye a cikin jiki ta hanyar jijiya. Ana ba da magungunan da ke ɗauke da bitamin da ma'adanai ta hanyar ɗigon ruwa ko allura na cikin jini, wanda ke ba da damar jiyya ta gudana cikin sauri ta cikin jini. A cewar Scope, gudanar da IV shine lokacin da ake ba da magani. majiyyaci yana amfani da bututu da ake kira cannula don saka abubuwa kai tsaye a cikin jijiya.Wannan na iya zama sakamako na gefe na magani ko ƙarancin abinci mai gina jiki.IV far ne na hali don samar da ruwa, kwayoyi, chemotherapy, da ƙarin jini ga marasa lafiya da suka bushe. .A lokacin mulkin IV, ana amfani da kayan aikin IV daban-daban irin su IV catheters, famfo jiko, na'urorin motsa jiki, da kayan aikin gudanarwa. Yana kawar da cututtuka na yau da kullum fiye da maganin baka.Yana da famfo na jiko wanda ke sarrafa adadin sinadarai da za a ba wa jiki kuma ana iya sa ido a hankali. Ana sa ran kasuwar intravenous ta duniya da na'urorin shiga cikin jijiya za su karu a tsawon lokacin hasashen. na ciwon sukari, hauhawar hatsarurrukan ababen hawa, da karuwar hanyoyin tiyata ana sa ran za su ciyar da masana'antar gaba. Har ila yau, masana'antar ana yin ta ne ta hanyar karuwar buƙatun hanyoyin zamani, kamar isar da magunguna marasa allura. COVID-19 Tasirin COVID-19 yana da A cikin marasa lafiya masu fama da cutar COVID-19 da ke da alaƙa da matsanancin damuwa na numfashi, ana gudanar da maganin IV (ARDS). An buga wani m adjuvant don kula da matsananciyar ARDS mai alaƙa da COVID-19 a cikin The Lancet Respiratory Medicine a ranar 11 ga Nuwamba, 2021 saboda Ikon daidaita ɗakunan rigakafi da yawa a lokaci guda.Saboda haka, tare da karuwa a yawan masu cutar COVID-19. ARDS masu alaka, buƙatar maganin IV da samfuran shiga cikin jijiya yana ƙaruwa. Abubuwan Ci gaban Kasuwa Ƙarfafa Ayyuka da Girman Yawan Jama'ar Geriatric Yawan cututtuka daban-daban masu buƙatar maganin ciwon jini ya karu a cikin shekaru goma da suka wuce. Cututtuka na yau da kullum kamar ciwon daji, gazawar koda da kuma ciwon daji. cututtukan zuciya, da kuma salon rayuwa daban-daban kamar hawan jini, ciwon sukari, kiba da damuwa, suna buƙatar kulawa mai zurfi yayin zaman asibiti. A cikin ƴan shekaru masu zuwa, ƙara nauyin cututtuka na yau da kullun kamar cututtukan zuciya, ciwon daji, bugun jini, da ciwon sukari. , Haɗe tare da yawan tsufa, za su ƙara buƙatar maganin jijiya. Ci gaban fasaha na ci gaba na ciki (na gefe da tsakiya), kayan haɗi tare da na'urorin aminci, da famfo jiko na tip suna daga cikin albarkatun fasaha waɗanda ke ba da gudummawa ga mafi aminci, mafi girma-ingancin magani na intravenous (na waje da tsakiya). IVT) aiki.Kamar yadda fasahar kiwon lafiya ta kasance mai rikitarwa, tare da tunani da tattaunawa a kowace rana ta hanyar kwararrun likitocin kiwon lafiya da ke cikin kulawar marasa lafiya a cikin sashin kulawa mai zurfi, fannin kulawa ya sami canje-canje masu mahimmanci saboda haɗakar da sababbin fasaha, da kuma yankan-baki jiko famfo daya daga cikin fasaha albarkatun don taimakawa wajen cimma mafi aminci da kuma mafi girma ingancin jijiya far (IVT) yi.Market Constraints Pump Kera na bukatar tsauraran dokoki da damuwa game da rikitarwa. Ana aiwatar da tsarin ba da lasisi don sababbin ayyukan a kusa da samar da famfo da haɓakawa. Bugu da ƙari, haɓakar samfurin tunowa saboda lahani na masana'antu zai rage jinkirin karɓar waɗannan hanyoyin kwantar da hankali. Misali, Fresenius Kabi ya tuna da Vigilant Agilia Drug Depot da Volumat MC Agilia Infusion Pump in Agusta 2019 saboda jiko jijjiga al'amurran da suka shafi, low-prioted Keep Vein Open (KVO) da sauran software kurakurai.Babban cikas ga ci gaban masana'antu shi ne rikitarwa hade da amfani da IV hanyoyin da IV kayayyakin jiko.Ƙarshen Mai amfani Outlook Based a karshen mai amfani, kasuwa an raba shi zuwa asibitoci, cibiyoyin tiyata na motar asibiti, da kuma dakunan shan magani.Yankin asibitin zai karbi kaso mafi girma na kudaden shiga a cikin jiyya na jini (IV) da kasuwar samun venous a cikin 2021. Wannan ya faru ne saboda karuwar adadin na tiyata da aka yi idan aka kwatanta da cibiyoyin tiyata na asibiti da kuma dakunan shan magani. Bugu da ƙari, an danganta girma da kashi ga karuwar amfani da maganin jijiya a cikin asibitoci, wanda ya hada da maganin rigakafi na ciki, magunguna ga marasa lafiya na comatose, magungunan da ba za a iya ɗaukar su da baki, shiga tsakani ba. Radiology, maganin ciwon daji, hemodialysis, maimaita taswirar jini, da ƙarin jini .Kasuwa don maganin IV da na'urorin samun venous yana haɓaka saboda ci gaban fasaha da saka hannun jari na asibiti.Aikace-aikacen Aikace-aikacen Dangane da aikace-aikacen, kasuwa an raba shi cikin sarrafa magunguna. , Samfuran tushen jini, hanyoyin abinci mai gina jiki da buffer, da tasoshin haɓakawa.A cikin 2021, sashin Faɗakarwa na Volume zai sami babban rabon kudaden shiga a cikin maganin jijiya (IV) da kasuwar samun venous. Ruwan ciki na iya zama da amfani ga ƙaramin adadin ruwa. -'yan wasa masu hankali; duk da haka, wannan ya kamata a ajiye shi ga 'yan wasa masu girma tare da tarihin bayyanar cututtuka masu karfi a karkashin kulawa mai kyau.Wasu 'yan wasa na iya amfana daga yin amfani da fadada. Jiyya na IV na yau da kullun ba shine mafi kyawun zaɓi ba.Nau'in Outlook Dangane da nau'in, kasuwa ta kasu kashi cikin catheters na ciki, famfo jiko, alluran hypodermic, tashar jiragen ruwa da za a dasa, da sauransu. maganin jijiya (IV) da kuma kasuwar shiga venous. Wannan ya faru ne saboda karuwar amfani da catheters IV a lokacin hanyoyin tiyata don maganin IV da kuma lokacin jigilar jini, magunguna, da sauran abubuwan gina jiki zuwa sassa daban-daban na jiki. An sanya su a cikin kogon jiki ko lumen.Canjin catheter wani nau'in catheter ne na ciki wanda ake amfani dashi don sadar da kwayoyi, ruwaye, ko wasu hanyoyin kwantar da hankali kai tsaye zuwa cikin jini. Yawancin lokuta ana shigar da su a cikin jijiya a hannu, ko da yake ana iya shigar da su a cikin jini. wuya, ƙirji, ko makwancinsa.Cibiyoyin bugun jini suna zuwa da girma da tsari iri-iri, gwargwadon yadda ake amfani da su.Hanyoyin yanki Dangane da yanki, kasuwar ta kasu kashi zuwa Arewacin Amurka, Turai, Asiya Pacific & Latin Amurka, Gabas ta Tsakiya & Afirka. .A cikin 2021, Arewacin Amurka shine yanki na gaba a cikin maganin jijiya (IV) da kasuwar samun venous ta hanyar ɗaukar mafi girman rabon kudaden shiga na kasuwa. Ana iya danganta haɓakar kasuwar yankin da haɓakar adadin marasa lafiya, haɓakar abubuwan da suka faru. hadurran zirga-zirgar ababen hawa, babban ci gaba a cikin lamuran rauni, da haɓaka saka hannun jari na tarayya don haɓaka ingantattun wuraren kiwon lafiya da ayyukan R&D. Rahoton bincike na kasuwa ya ƙunshi nazarin manyan masu ruwa da tsaki na kasuwa. Manyan kamfanonin da aka bayyana a cikin rahoton sun haɗa da B. Braun Melsungen AG, Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGaA, Cardinal Health, Inc., Pfizer, Inc., Teleflex, Inc., Baxter International, Inc., Smiths Group PLC da AngioDynamics, Inc. Ƙaddamar da Dabarun a cikin Jiki (IV) ) Therapy and Intravenous Access Market Maris 2022: Fresenius Kabi ya sanya hannu kan wata yarjejeniya don siyan Fresenius Kabi, kamfanin kula da lafiya na duniya. Sayen, wanda aka tsara don haɗa tsarin haɓakar Ivenix' infusions na Fresenius Kabi na jiko na jiko da samfuran jiko, zai kawo sakamako mai kyau. Babban haɗin samfuran zuwa asibitocin Amurka.Disamba 2021: Baxter ya samar da haɗin gwiwa tare da mai ba da fasahar likitancin Amurka Hillrom.Ta hanyar wannan haɗin gwiwar, kamfanonin biyu suna da niyyar haɗa manyan kasuwancin fasahar likitanci guda biyu don cimma burin hangen nesa na canza tsarin kiwon lafiya na duniya da haɓaka kulawar marasa lafiya. .May 2021: Smiths Medical ya samar da haɗin gwiwa tare da kamfanin fasahar likitanci Ivenix.Ta hanyar wannan haɗin gwiwa, kamfanonin biyu suna nufin ba da dama ga hanyoyin sarrafa jiko. Bugu da ƙari, Smiths Medical zai samar da dabarun zuba jarurruka a cikin haɗin gwiwa na dogon lokaci da aka tsara don juyin juya halin sarrafa hadawa. da kuma inganta lafiyar mara lafiya, yayin da ke haduwa da bukatun kiwon lafiya wadanda kasuwar lafiya, fa'ida ta hanyar inganta jagorar da ke haifar da jagorar ciki ingantattun kayan aiki don ƙarfafa ma'aikatan aikin jinya don cimma nasarar farko da kuma taimakawa wajen guje wa rikice-rikicen da ke tattare da maganin jiyya na IV. Yuli 2019: Baxter ya karɓi izinin Hukumar Abinci da Magunguna ta Amurka (FDA) don Myxredlin. Amincewar ta ba da izinin insulin nan da nan don jiko na ciki a cikin asibitoci. da sauran saitunan kulawa mai zurfi kuma yana da tsawon rai na kwanaki 30 ko watanni 24 a zafin jiki idan an sanya shi a cikin marufi na asali don tabbatar da kariya daga haske. • Kayayyakin Jini • Kayayyakin Jini da Maganin Buffer • Ruwan Yaduwa ta Nau'i • Catheters na Jiki • Jiko Pumps • Gilashin allura • Tashar ruwa da za a dasa • Sauran ta Geography • Arewacin Amurka o USo Kanadao Mexico Sauran Arewacin Amurka • Turai Jamus o UKo Faransa Rasha Spain Italiya o Sauran Turai • Asiya Pasifik China ko Japan Indiya Koriya Singapore Malaysia o Sauran Asiya Pacific • LAMEAo Brazil Argentina UAE Saudi Arabia South Africa Nigeria LAMEA Rest Company Profile • B. Braun Melsungen AG • Medtronic PLC• Kamfanin Terumo • Fresenius SE & Co. KGaA• Cardinal Health, Inc.• Pfizer, Inc.• Teleflex, Inc.• Baxter International, Inc.• Smiths Group PLC• AngioDynamics, Inc. Kyauta na Musamman • Ƙarfafa Ƙarfafawa • Mafi Girman Teburan Kasuwa & Bayanai • Samfurin Biyan Kuɗi Ya samuwa • Garanti Mafi kyawun Farashi • Tabbatar da Binciken Bincike Bayan Talla da Goyan bayan 10% Keɓancewa Karanta cikakken rahoton kyauta: https://www .reportlinker.com/p06283441/?utm_source=GNWAbout ReportlinkerReportLinker shine mafitacin bincike na kasuwa mai nasara.Reportlinker ya gano kuma yana tsara sabbin bayanan masana'antu don ku sami duk binciken kasuwa da kuke buƙata nan da nan a wuri ɗaya.